Overview

Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, parallel, open-label study of patients who have responded to treatment in the acute phase of their manic or mixed episode, with or without psychotic symptoms, with olanzapine in mono or co-therapy, and who are in syndromic and symptomatic remission at the time of enrollment into the study.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine